Universal CD19 CAR-T

Phase 1Cell therapy

XXuanwu Hospital, Beijing

Universal CD19 CAR-T is one of 48 small molecule programs targeting Autoimmune Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autoimmune DiseaseNot yet recruiting

Autoimmune DiseasePhase 1

Not yet recruiting

Competition

Competitive Landscape

74 competitors in Autoimmune Disease

#DrugCompanyPhaseTrials

Atgam

Novartis

Phase 2

2 2

Cytosar

Teva

Phase 2

1 3

Rayos

RRoxane Laboratories

Phase 2

2 4

Alkeran

AApotex Inc.

Phase 2

1 5

Vepesid

AAvyxa

Phase 2

1 6

Bicnu

MMelissa K Accordino

Phase 2

1 7

Fludara

Sanofi

Phase 1

8 8

Rituxan

Roche

Phase 1

2 9

CAR-T Cell

PPersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 2

3 10

Anti-CD19 CAR-T Cells

TThe Children's Hospital of Zhejiang University School of Medicine

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Autoimmune Disease

NCT06485232

Clinical

Trials by Indication[1]

Autoimmune Disease1 trial

Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.

Not yet recruiting·XXuanwu Hospital, Beijing·Phase 1·NCT06485232·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Universal CD19 CAR-T. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Universal CD19 CAR-T compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Universal CD19 CAR-T. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xuanwu Hospital, Beijing company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: XXuanwu Hospital, Beijing

Universal CD19 CAR-T

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Autoimmune Disease1 trial

References

Drug Info

Quick Facts

Related News